Stein M, Link D P
Department of Radiology, University of California Davis Medical Center, Sacramento, USA.
J Vasc Interv Radiol. 1999 Mar;10(3):363-71. doi: 10.1016/s1051-0443(99)70044-8.
To evaluate the safety and efficacy of portal reconstruction in patients with symptomatic spleno-mesenteric-portal venous thrombosis.
Portal reconstruction was attempted in 21 patients (seven women, 14 men; mean age, 53.6 years +/- 15.2) with chronic thrombosis of the portal vein alone (n = 8), splenic vein alone (n = 3), or portal, mesenteric, and splenic veins (n = 10). Indications for the procedure were bleeding varices (n = 15), ascites (n = 2), hypersplenism (n = 2), and enteropathy (n = 2). Sixteen procedures were started transhepatically and of these seven were converted to a transjugular intrahepatic portosystemic shunt (TIPS) after successful recanalization of the thrombosed vein. In six patients reconstructions were performed using an intrahepatic portal vein as outflow. Five procedures were performed primarily as TIPS. Wallstents dilated to 7-10 mm were used for reconstruction. The mean follow-up period was 15.2 months +/- 15.9.
Technical success of portal reconstruction was 85.7% (18 of 21). Thirty-day mortality was 14.3% (three of 21) but was not procedural related. The cumulative rates of survival, primary patency, and palliation at 43 months of follow-up were 61.2% +/- 13.5%, 63.5% +/- 15.3%, and 31.7% +/- 15.7%, respectively. Secondary patency was 79.1% +/- 13.8%. The only predictor of mortality was the presence of liver disease (P = .001, Cox regression).
Portal reconstruction is a safe and effective treatment option for patients with symptomatic chronic portal thrombosis. Liver disease predisposes to a higher mortality.
评估有症状的脾 - 肠系膜 - 门静脉血栓形成患者进行门静脉重建的安全性和有效性。
对21例患者(7例女性,14例男性;平均年龄53.6岁±15.2岁)尝试进行门静脉重建,这些患者分别为单纯门静脉慢性血栓形成(n = 8)、单纯脾静脉血栓形成(n = 3)或门静脉、肠系膜静脉和脾静脉血栓形成(n = 10)。手术指征为静脉曲张出血(n = 15)、腹水(n = 2)、脾功能亢进(n = 2)和肠病(n = 2)。16例手术经肝开始,其中7例在血栓形成的静脉成功再通后转为经颈静脉肝内门体分流术(TIPS)。6例患者使用肝内门静脉作为流出道进行重建。5例手术最初作为TIPS进行。使用扩张至7 - 10毫米的Wallstents进行重建。平均随访期为15.2个月±15.9个月。
门静脉重建的技术成功率为85.7%(21例中的18例)。30天死亡率为14.3%(21例中的3例),但与手术无关。随访43个月时的累积生存率、原发性通畅率和缓解率分别为61.2%±13.5%、63.5%±15.3%和31.7%±15.7%。继发性通畅率为79.1%±13.8%。死亡的唯一预测因素是肝病的存在(P = 0.001,Cox回归)。
门静脉重建是有症状的慢性门静脉血栓形成患者的一种安全有效的治疗选择。肝病易导致较高的死亡率。